



Cytoplasmic dynein regulates the subcellular localization of
sphingosine kinase 2 to elicit tumor-suppressive functions in
glioblastoma
Heidi A. Neubauer1,2 ● Melinda N. Tea1 ● Julia R. Zebol1 ● Briony L. Gliddon1 ● Cassandra Stefanidis1,3 ●
Paul A. B. Moretti1 ● Melissa R. Pitman1 ● Maurizio Costabile1,3 ● Jasreen Kular1 ● Brett W. Stringer 4 ●
Bryan W. Day4 ● Michael S. Samuel 1,5 ● Claudine S. Bonder1,5 ● Jason A. Powell1,5 ● Stuart M. Pitson 1,2,5
Received: 28 December 2017 / Revised: 10 July 2018 / Accepted: 24 August 2018 / Published online: 24 September 2018
© The Author(s) 2018. This article is published with open access
Abstract
While the two mammalian sphingosine kinases, SK1 and SK2, both catalyze the generation of pro-survival sphingosine 1-
phosphate (S1P), their roles vary dependent on their different subcellular localization. SK1 is generally found in the
cytoplasm or at the plasma membrane where it can promote cell proliferation and survival. SK2 can be present at the plasma
membrane where it appears to have a similar function to SK1, but can also be localized to the nucleus, endoplasmic
reticulum or mitochondria where it mediates cell death. Although SK2 has been implicated in cancer initiation and
progression, the mechanisms regulating SK2 subcellular localization are undefined. Here, we report that SK2 interacts with
the intermediate chain subunits of the retrograde-directed transport motor complex, cytoplasmic dynein 1 (DYNC1I1 and
-2), and we show that this interaction, particularly with DYNC1I1, facilitates the transport of SK2 away from the plasma
membrane. DYNC1I1 is dramatically downregulated in patient samples of glioblastoma (GBM), where lower expression of
DYNC1I1 correlates with poorer patient survival. Notably, low DYNC1I1 expression in GBM cells coincided with more
SK2 localized to the plasma membrane, where it has been recently implicated in oncogenesis. Re-expression of DYNC1I1
reduced plasma membrane-localized SK2 and extracellular S1P formation, and decreased GBM tumor growth and tumor-
associated angiogenesis in vivo. Consistent with this, chemical inhibition of SK2 reduced the viability of patient-derived
GBM cells in vitro and decreased GBM tumor growth in vivo. Thus, these findings demonstrate a tumor-suppressive
function of DYNC1I1, and uncover new mechanistic insights into SK2 regulation which may have implications in targeting
this enzyme as a therapeutic strategy in GBM.
Introduction
Sphingosine 1-phosphate (S1P) is an important signaling
lipid that regulates many cellular processes, including cell
survival, proliferation, apoptosis, migration and differ-
entiation [1]. Cellular S1P is generated from sphingosine by
the sphingosine kinases (SKs), SK1 and SK2. Many sig-
naling pathways activated by S1P promote cell survival and
proliferation, whereas sphingosine, and its precursor cer-
amide, are both pro-apoptotic molecules [2]. Interestingly,
despite both enzymes catalyzing the formation of S1P, SK1
and SK2 have both overlapping and divergent functions
within the cell [1, 3], with these differing functions dictated
by their differential subcellular localization [4].
SK1 is largely cytoplasmic, but we have previously
shown that phosphorylation and activation promotes SK1
translocation to the plasma membrane [5] where it can
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facilitate pro-survival, pro-proliferative signaling [6–8]. As
such, targeting SK1 has demonstrated anti-tumor effects [9].
Similarly, we recently showed that SK2 can mediate
tumorigenesis, and it too was found localized to the plasma
membrane to increase S1P levels in this setting [9]. How-
ever, the roles of SK2 are complex and, unlike SK1, SK2
can also promote cell cycle arrest and cell death under
certain conditions, where these functions appear to require
changes to SK2 subcellular localization. Specifically, SK2
localization to the nucleus and internal organelles can
confer pro-apoptotic, anti-proliferative functions, whereas
plasma membrane localization drives pro-proliferative and
oncogenic signaling [3]. However, the mechanisms reg-
ulating SK2 translocation between various cellular com-
partments in order to effect changes in its functions are
currently unexplored.
In this study, we identified cytoplasmic dynein 1 inter-
mediate chains 1 and 2 (DYNC1I1 and DYNC1I2) as SK2-
interacting proteins. We demonstrate that SK2 interacts with
the cytoplasmic dynein complex in cells and, consistent
with the retrograde transport function of dynein, interaction
with DYNC1I1-containing dynein complexes appears to
facilitate transport of SK2 away from the cell periphery.
Furthermore, we report a dramatic downregulation of
DYNC1I1 in glioblastoma (GBM), which correlates with
poorer patient survival, and demonstrate that lower
DYNC1I1 expression in GBM cells coincides with more
SK2 localized to the plasma membrane. Notably, re-
expression of DYNC1I1 in GBM cells reduced plasma
membrane-localized SK2 and extracellular S1P formation
and, strikingly, decreased tumor growth and tumor-
associated angiogenesis in vivo. Consistently, chemical
inhibition of SK2 showed efficacy against human GBM
patient-derived cells in vitro and decreased GBM xenograft
tumor growth in vivo. Together, our findings indicate a
novel tumor-suppressive function of DYNC1I1 in GBM via
dynein-mediated regulation of SK2.
Results
Dynein intermediate chains are SK2-interacting
proteins
To better understand the mechanisms of SK2 regulation, a
yeast two-hybrid screen was performed to identify novel
SK2-interacting proteins. One candidate protein was iden-
tified as cytoplasmic dynein 1 intermediate chain 2
(DYNC1I2; hereafter referred to as IC2), as represented by
the isolation of a partial complementary DNA (cDNA)
encoding the c-terminal 173 amino acids of this 67 kDa
protein (residues 440–612). An association between full-
length IC2 and SK2 was verified by co-
immunoprecipitation in mammalian cells co-expressing
the two proteins (Fig. 1a). Two mammalian cytoplasmic
dynein intermediate chain isoforms exist, the ubiquitously
expressed IC2 identified in the yeast two-hybrid screen and
IC1 (DYNC1I1) which is expressed most abundantly in the
brain [10]. Interestingly, compared to IC2, the interaction
between SK2 and IC1 appeared stronger (Fig. 1b),
potentially suggesting an important isoform-specific role
for IC1 in interacting with SK2.
Next, to confirm interaction of the endogenous proteins,
SK2 was immunoprecipitated from murine brain lysates,
which demonstrated a robust co-immunoprecipitation of
endogenous dynein intermediate chains (ICs; Fig. 1c).
Given that the ICs are found physiologically as dimeric
subunits of the dynein complex, the presence of other
dynein components within the SK2 immunocomplexes was
examined. Indeed, an association of SK2 with the dynein
light intermediate chain 1 (LIC1) subunit was observed, and
also with the p150 subunit from the dynactin complex (Fig.
1c), which is a regulatory complex that plays important
roles in facilitating almost all dynein functions [11].
Immunofluorescence analysis of endogenous SK2 and
dynein ICs was then performed to examine their localiza-
tion. Consistent with their physiological interaction, both
proteins showed considerable subcellular co-localization in
HEK293 cells, mainly at cytoplasmic and peri-nuclear
regions (Fig. 1d). Further confirmation of the physiological
interaction of endogenous SK2 and dynein ICs was
obtained by in situ proximity ligation assays (PLAs), which
again demonstrated a clear SK2–IC interaction mainly at
cytoplasmic and peri-nuclear regions (Fig. 1e). Appropriate
single antibody controls confirmed that detection of both
proteins together was required to produce PLA signals (Fig.
1e). Taken together, these data demonstrate that SK2
interacts with dynein ICs as a part of the physiological
dynein complex in cells.
SK2 subcellular localization is regulated by dynein
The interaction and subcellular localization of SK2–IC
complexes is consistent with the role of dynein in trans-
porting cargo in a retrograde direction along microtubules,
which eventually accumulate at the microtubule-organizing
center (MTOC) located adjacent to the nucleus [12, 13].
Given that SK2 co-localized with dynein ICs mainly at peri-
nuclear regions of the cell, the involvement of dynein in the
retrograde-directed transport of SK2 was examined. To do
this, small interfering RNA (siRNA)-mediated IC1 and IC2
knockdown was performed in HEK293 cells which express
both IC proteins, and ectopic expression of SK2 was
employed to better visualize its subcellular localization.
Consistent with the localization of endogenous SK2 in these
cells, ectopically expressed SK2 had a predominantly peri-
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nuclear localization (Fig. 2a). Upon RNA interference
(RNAi)-mediated knockdown of IC1 however, this changed
to strong plasma membrane localization of SK2 (Fig. 2a, b).
Notably, however, no effect on the subcellular localization
of SK2 was observed with IC2 knockdown (Fig. 2a–c).
Therefore, these data are consistent with the notion that SK2
is transported by IC1-containing dynein complexes in a
retrograde direction away from the plasma membrane.
Dynein IC1 is downregulated in glioblastoma and
correlates with poor patient survival
At the plasma membrane, S1P produced by the SKs can be
exported from the cell where it can act on a family of five
S1P receptors to promote cell survival and proliferation, as
well as contribute to oncogenic signaling pathways [1]. This
role is well established for SK1 [6], and we have recently
reported a role for SK2 in mediating oncogenesis which
Fig. 1 SK2 interacts with dynein IC. a HEK293 cells were transfected
with empty vector (EV) or a vector encoding HA-tagged IC2, either
individually or in combination with a vector encoding FLAG-tagged
SK2. SK2 was immunoprecipitated from cell lysates with anti-FLAG
antibodies, and co-immunoprecipitated IC2 was detected by immu-
noblotting with anti-HA antibodies. Expression levels of IC2 in the
lysates were confirmed by immunoblotting with anti-HA antibodies
(Lysate). Immunoprecipitates were also probed with anti-FLAG anti-
bodies to confirm the presence of SK2. Blots shown are representative
of at least five independent experiments. b HEK293 cells were
transfected with empty vector (EV) or a vector encoding FLAG-tagged
SK2, either individually or in combination with a vector encoding HA-
tagged IC1 or HA-tagged IC2. Lysates were pre-cleared with Protein
G µbeads. Co-immunoprecipitation and immunoblotting analyses were
then performed as described in (a). Blots shown are representative of
three independent experiments. c SK2 was immunoprecipitated from
murine whole brain lysate using anti-SK2 antibodies. Co-
immunoprecipitated dynein intermediate chains (IC), light inter-
mediate chain 1 (LIC1) and dynactin p150 were detected by immu-
noblotting with anti-IC, anti-LIC1 and anti-dynactin p150 antibodies,
respectively. Expression levels of these proteins in the mouse brain
lysate were confirmed by immunoblot analyses with their respective
antibodies (Lysate). Lysates and immunoprecipitates were also probed
with anti-SK2 antibodies to confirm expression and immunoprecipi-
tation of SK2. H/C designates the heavy chain IgG band. Blots shown
are representative of three independent experiments. d Immuno-
fluorescence staining and confocal microscopy demonstrating co-
localization of SK2 and dynein IC in HEK293 cells. SK2 (green) was
detected using anti-SK2 antibodies and dynein IC (red) was detected
using anti-IC antibodies. Nuclei were highlighted using DAPI (blue).
Images are representative of at least 100 cells, from three independent
experiments. Scale bar= 10 μm. e Immunofluorescence analysis and
confocal microscopy demonstrating direct interactions between SK2
and dynein IC, using the Duolink® in situ PLA system with anti-SK2
(1:300; ECM Biosciences) and anti-IC antibodies (1:300) in HEK293
cells (top panels). Each red dot indicates a single direct interaction.
Nuclei were highlighted using DAPI (blue). Differential interference
contrast images are also shown (bottom panels). Images are repre-
sentative of at least 100 cells, from three independent experiments.
Scale bar= 10 μm
Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit. . . 1153
coincided with increased localization of SK2 at the plasma
membrane and increased extracellular S1P formation [9].
Therefore, the increase in plasma membrane-localized SK2
upon dynein IC knockdown raised the question of whether
downregulation of the dynein ICs could contribute to an
oncogenic phenotype.
To explore this, a broad gene expression analysis of both
IC1 (DYNC1I1) and IC2 (DYNC1I2) was performed on a
panel of different human cancers, using public gene
expression datasets available from the Oncomine database
[14]. Strikingly, IC1 was found to be significantly down-
regulated, compared to corresponding normal tissues, in a
vast range of different cancers, including brain, ovarian,
bladder, prostate, colon, breast, uterine, cervical and lym-
phoma (Fig. 3a). Importantly, IC2 gene expression levels in
these cancer datasets were generally unaltered, compared to
corresponding normal tissues (Supplementary Figure S1),
demonstrating that there is no substantial compensation for
IC1 loss across these cancer types. As IC1 expression is
highest in brain tissues [10], it was particularly notable that
a dramatic 17-fold downregulation in IC1 expression
occurred in GBM patient samples compared to normal brain
tissue (Fig. 3a, b). Interestingly, this was not specific to a
particular GBM subtype, as IC1 expression was similarly
downregulated in all three molecular subtypes of GBM [15,
16] (Supplementary Figure S2A), whereas again, IC2
expression was unchanged across all (Supplementary Figure
S2B). Kaplan–Meier survival analysis of patients with
GBM also demonstrated that low expression of IC1 corre-
lated with poorer overall survival compared to patients with
higher IC1 expression (Fig. 3c). Together, these analyses
suggest that IC1 may play a tumor-suppressive role in
cancer, and particularly in GBM.
IC1 expression levels regulate plasma membrane
localization of SK2
To examine the mechanisms behind the potential role of
IC1 as a tumor suppressor in GBM, the expression of IC1
was initially examined in two commonly used GBM cell
lines, U-87 and U-251. Notably, U-251 cells had sig-
nificantly lower levels of IC1 messenger RNA (mRNA; Fig.
4a) and protein (Fig. 4b) compared with U-87 cells. Since
we observed SK2 localized to the plasma membrane with
IC1 knockdown (Fig. 2), we reasoned that the low levels of
IC1 observed in the U-251 cells may result in increased and/
or prolonged localization of SK2 at the plasma membrane.
Indeed, examining the localization of endogenous SK2 by
immunofluorescence staining demonstrated prominent
plasma membrane localization of SK2 in U-251 cells, but
not in U-87 cells (Fig. 4c, d), consistent with higher levels
of IC1 in U-87 cells (Fig. 4a–d) and further suggesting a
role for IC1 in regulating SK2 subcellular localization.
Next, we examined whether re-expression of IC1 in U-
251 cells was sufficient to reduce SK2 localization at the
plasma membrane. Taking an approach previously reported
by others [17, 18], we generated U-251 cells stably
expressing IC1-green fluorescent protein (GFP) at low
levels, similar to endogenous IC, as confirmed by immu-
noblot (Supplementary Figure S3A). Importantly,
Fig. 2 Dynein regulates the subcellular localization of SK2. a Immu-
nofluorescence analysis and confocal microscopy of HEK293 cells
transfected with a vector encoding FLAG-tagged SK2 and either
negative control (Ctl) siRNA, IC1 siRNA or IC2 siRNA for 48 h. SK2
(red) was detected using anti-FLAG antibodies. Images are repre-
sentative of at least 200 cells observed from three independent
experiments. Scale bar= 10 µm. IC1 and IC2 knockdown was asses-
sed by qRT-PCR with levels of IC1 and IC2 mRNA normalized to
GAPDH mRNA (**p < 0.01, ****p < 0.0001; Student's unpaired two-
tailed t-test). Cells with knockdown of IC1 (b) or IC2 (c) were scored
based on the presence of plasma membrane (PM)-localized FLAG-
tagged SK2. A minimum of 200 cells were scored per treatment. Data
were graphed as mean (±SD) of triplicate wells from a single
experiment, representative of three independent experiments (*p <
0.05; Student's unpaired two-tailed t-test)
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exogenous IC1-GFP displayed peri-nuclear localization
(Supplementary Figure S3B), formed interactions with
endogenous dynein IC and LIC1 subunits (Supplementary
Figure S3C) and exhibited high-level co-localization with
LIC1 in cells (Supplementary Figure S3D), confirming that
the fusion protein was incorporating into endogenous
dynein complexes. Thus, we examined the localization of
SK2 in these cells. Whereas GFP control cells had promi-
nent plasma membrane localization of SK2, this was
significantly decreased in cells overexpressing IC1-GFP
(Fig. 4e, f). Concomitant with a loss of SK2 at the plasma
membrane, there was also a significant reduction in the rate
of extracellular S1P formation in the U-251 cells expressing
IC1-GFP compared with control cells (Fig. 4g). Therefore,
collectively these data demonstrate that re-expression of
IC1 in U-251 GBM cells can reinstate dynein-mediated
translocation of SK2 away from the plasma membrane.
Fig. 3 Dynein IC1 is downregulated in GBM which correlates with
poorer patient survival. a Box plots showing human cancers with
significant (p < 1 × 10–4) downregulation of IC1 (DYNC1I1) mRNA.
Data were extracted from the Oncomine database, from the following
studies (left to right): 1, TCGA Brain (glioblastoma); 2, Murat Brain
(glioblastoma); 3, Sun Brain (glioblastoma, oligodendroglioma, ana-
plastic astrocytoma); 4, Yoshihara Ovarian (ovarian serous adeno-
carcinoma); 5, Sanchez-Carbayo Bladder 2 (infiltrating bladder
urothelial carcinoma, superficial bladder cancer); 6, Lee Bladder
(superficial bladder cancer); 7, Welsh Prostate (prostate carcinoma); 8,
Lapointe Prostate (prostate carcinoma); 9, Taylor Prostate 3 (prostate
carcinoma); 10, TCGA Colorectal (colon adenocarcinoma); 11, TCGA
Breast (invasive ductal breast carcinoma, invasive lobular breast car-
cinoma, invasive breast carcinoma, mixed lobular and ductal breast
carcinoma); 12, Finak Breast (invasive breast carcinoma stroma); 13,
Curtis Breast (mucinous breast carcinoma, invasive lobular breast
carcinoma, invasive ductal breast carcinoma, tubular breast carci-
noma); 14, Crabtree Uterus (uterine corpus leiomyoma); 15, Pyeon
Multi-cancer (cervical cancer); 16, Compagno Lymphoma (activated
B-cell-like diffuse large B-cell lymphoma). b TCGA brain dataset
showing a mean 17-fold downregulation of IC1 mRNA levels in
human glioblastoma (GBM) tissue, compared with levels in normal
human brain tissue. Statistical significance (****p < 0.0001) was
determined using Student's unpaired two-tailed t-test. c IC1 mRNA
expression levels and survival data from human GBM patients were
obtained from the REMBRANDT dataset, and Kaplan–Meier survival
curves were plotted for patients with tumors having the lowest 10%
(low IC1) and highest 90% (high IC1) of IC1 expression levels. Sta-
tistical significance was determined using a two-sided log-rank test
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Re-expression of IC1 in U-251 GBM cells reduces
neoplastic growth in vitro and in vivo
As plasma membrane-localized SK can promote oncogen-
esis [6], we hypothesized that a loss of SK2 from the plasma
membrane, and a consequent decrease in the rate of extra-
cellular S1P formation, resulting from re-expression of IC1
may reduce the oncogenic potential of these GBM cells.
Indeed, the U-251 cells re-expressing IC1 had significantly
attenuated anchorage-independent growth compared to
control cells, as assessed by colony formation assays in soft
agar which showed a clear IC1-induced decrease in both
colony number and size (Fig. 5a–c).
To determine if this reduced oncogenic potential in vitro
corresponded to a decrease in tumor growth in vivo, U-251
cells re-expressing IC1 or control U-251 cells were sub-
cutaneously engrafted into the flanks of NOD/SCID (non-
obese diabetic/severe combined immunodeficiency) mice,
and tumor growth measured over time. Re-expression of
IC1 decreased GBM tumor growth by approximately 50%
compared with tumors from control U-251 cells (Fig. 5d).
The presence of re-expressed IC1 in the excised tumors was
Fig. 4 IC1 expression levels regulate plasma membrane localization of
SK2. a Relative IC1 (DYNC1I1) mRNA expression levels in U-87 and
U-251 human GBM cell lines. Gene expression levels were deter-
mined by qRT-PCR (comparative quantification, normalized to
GAPDH). Graphs are plotted as mean (±SEM) of data from three
independent experiments (**p < 0.01; Student’s unpaired two-tailed t-
test). b Immunoblot analyses of IC1 and SK2 protein expression in U-
87 and U-251 cell lines, using anti-IC1 and anti-SK2 (Proteintech)
antibodies. Immunoblotting for α-tubulin was performed as a loading
control. Blots are representative of three independent experiments. c
Immunofluorescence staining and confocal microscopy showing
endogenous SK2 localization in U-87 and U-251 GBM cells. SK2
(green) was detected using anti-SK2 antibodies (1:300; ECM Bios-
ciences), and nuclei were stained with DAPI (blue). Arrows denote
distinct plasma membrane localization of SK2. Scale bar= 10 μm. d
Cells described above were visualized by confocal microscopy and
scored based on the presence or absence of distinct plasma membrane
(PM)-localized SK2 staining. A minimum of 200 cells were scored per
cell type. Data were graphed as mean (±SEM) from three independent
experiments (**p < 0.01; Student's unpaired two-tailed t-test). e
Localization of endogenous SK2 in U-251 cells stably expressing GFP
alone (empty vector; EV) or IC1-GFP was examined by confocal
microscopy. IC1-GFP or GFP were visualized via their GFP tag
(green) and SK2 via immunofluorescence of the endogenous protein
using anti-SK2 antibodies (red; 1:300; ECM Biosciences). F-actin was
stained using Phalloidin (cyan), and nuclei were highlighted using
DAPI (blue). Arrows denote distinct plasma membrane localization of
SK2. Images are representative of more than 100 cells, from 3 inde-
pendent experiments. Scale bar= 10 μm. f Cells described above were
visualized by confocal microscopy and scored based on the presence
or absence of distinct plasma membrane (PM)-localized SK2 staining.
A minimum of 200 cells were scored per cell line. Data were graphed
as mean (±SEM) from three independent experiments (**p < 0.01;
Student's unpaired two-tailed t-test). g The rate of extracellular S1P
formation was determined from intact U-251 cells stably expressing
GFP (EV) or IC1-GFP. Analyses were performed in quadruplicate and
data are graphed as mean ± SD, normalized to cell number (**p < 0.01;
Student's unpaired two-tailed t-test)
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confirmed by immunoblot analyses (Supplementary Figure
S4). Reduced tumor growth can be a consequence of
decreased infiltrating blood vessels, limiting nutrients and
oxygen available to the tumor. Since extracellular S1P plays
an important role in mediating angiogenesis and blood
vessel infiltration into tumor tissue [19], and given that we
observed reduced extracellular S1P upon stable over-
expression of IC1 in vitro, we assessed tumor vasculariza-
tion by CD31 staining of tumor sections. Notably, there was
a significant reduction in the number of CD31-positive
vessels present in tumors formed from U-251 cells re-
expressing IC1, compared to the tumors from control U-251
cells (Fig. 5e).
Inhibition of SK2 induces GBM cell death and
reduces neoplastic growth in vitro and in vivo
Since our findings indicated that IC1 may act as a tumor
suppressor in GBM via attenuating the plasma membrane
localization and oncogenic signaling of SK2, we next
examined the effects of SK2 inhibitors on GBM cells. Both
K145, a selective SK2 inhibitor [20], and MP-A08, a dual
SK1/SK2 inhibitor with greater potency against SK2 [21],
effectively blocked the proliferation of U-251 cells (Fig. 6a,
b). Notably, U-87 cells were less sensitive to both K145 and
MP-A08 (Fig. 6c), consistent with the higher levels of IC1
and lack of plasma membrane-localized SK2 in these cells
(Fig. 4). The effect of K145 (Fig. 6d–f) and MP-A08
(Supplementary Figure S5) was also assessed against a
panel of low-passage primary patient GBM cell lines
established from patients with classical, mesenchymal or
proneural molecular subtypes of GBM. Indeed, consistent
with the universal downregulation of IC1 across these three
GBM subtypes (Supplementary Figure S2A), all GBM
subtypes appeared similarly sensitive to SK2 inhibition.
Notably, use of K145, MP-A08 and another SK2 inhi-
bitor ABC294640 [22] in anchorage-independent colony
formation assays resulted in a dose-dependent reduction in
the number of colonies formed by U-251 cells (Fig. 7a–c),
confirming that targeting SK2 has anti-neoplastic activity in
Fig. 5 IC1 re-expression in U-251 cells reduces neoplastic growth
in vitro and in vivo. a Anchorage-independent growth of U-251 cells
stably expressing GFP alone (empty vector; EV) or IC1-GFP was
evaluated using colony formation assays in soft agar. Representative
images of colonies from each group are shown. Average number of
colonies (b) and colony size (c) were quantified and are graphed as
mean (±SD) from quadruplicate wells of one experiment, representa-
tive of three independent experiments (**p < 0.01; Student's unpaired
two-tailed t-test). d NOD/SCID mice were subcutaneously engrafted
with U-251 cells stably expressing IC1-GFP, or GFP alone (EV), and
caliper measurements of palpable tumors were taken over 30 days.
Mean tumor volumes are shown (±SEM; n= 6–7 per group). Statis-
tical analysis on all data points was performed by two-way ANOVA. e
Tumors derived from U-251 cells stably expressing IC1-GFP or GFP
(EV) were sectioned, and CD31-positive vessels were examined by
immunohistochemical staining with anti-CD31 antibodies. Repre-
sentative images for each group are shown. The number of CD31-
positive vessels were quantified and averaged from at least four ran-
dom fields of view per tumor, at ×20 magnification, and are graphed
with means (n= 6 per group; ***p < 0.001; Student's unpaired two-
tailed t-test). All scale bars= 100 μm
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these cells. We next examined in vivo efficacy of targeting
SK2 on the growth of GBM xenografts in mice. NOD/SCID
mice bearing U-251 flank xenografts were treated with
K145 daily at 30 mg/kg for 3 weeks. K145 significantly
reduced tumor growth (Fig. 7d) and, consistent with the
effects of IC1 re-expression (Fig. 5e), targeting SK2 with
K145 also reduced tumor vasculature as signified by a
reduction in CD31-positive blood vessels (Fig. 7e). Fur-
thermore, TUNEL (terminal deoxynucleotidyl transferase
dUTP nick end labeling) fluorescence analysis and Ki67
immunohistochemistry revealed that K145 treatment resul-
ted in both a significant increase in tumor cell apoptosis
(Fig. 7f) and a trend towards reduced tumor cell prolifera-
tion (Fig. 7g), further consistent with the observed reduction
in tumor growth.
Discussion
The roles and regulation of SK2 remain poorly understood.
In this study we demonstrated that SK2 interacts with the
cytoplasmic dynein complex, via dynein ICs, which trans-
ports SK2 away from the cell periphery and thus regulates
its subcellular localization, which is critical for SK2 func-
tion (Fig. 8) [4]. Furthermore, we report that this novel SK2
regulatory mechanism has implications in GBM, where the
expression of the IC1 subunit is heavily downregulated and
correlates with poorer GBM patient survival. Indeed, our
findings demonstrate an interplay between the down-
regulation of IC1 in GBM and an increase in SK2 plasma
membrane localization, which was decreased by re-
expression of IC1, resulting in reduced GBM tumor
growth in vivo. Consistent with this, directly targeting SK2
with chemical inhibitors also showed anti-GBM activity
in vitro, including in primary patient GBM cell lines
representing the three molecular subtypes of GBM, and
reduced GBM tumor growth in vivo. Overall, our work
suggests that IC1 can act as a tumor suppressor in GBM via
the regulation of SK2, and that SK2 is a promising target for
examination as an anti-GBM therapy.
It is well accepted that the subcellular localization of the
SKs, and hence the location of S1P production, can give
Fig. 6 SK2 inhibition blocks
growth of U-251 GBM cells and
patient-derived cells from all
molecular subtypes of GBM.
Viability of U-251 GBM cells
cultured for 72 h in the indicated
concentrations of K145 (a) or
MP-A08 (b) in the presence of
0.5% FBS was determined by
MTS assay. Values are
displayed as % vehicle control
(DMSO), mean ± SEM (n= 3).
c Comparison of the viability of
U-251 and U-87 GBM cells
cultured for 48 h in the presence
of 6 μM K145 or 20 μM MP-
A08 (*p < 0.05, **p < 0.01;
Student's unpaired two-tailed t-
test). Viability of primary GBM
cells of low passage, established
from patients with d classical, e
mesenchymal and f proneural
molecular subtype GBM,
cultured for 72 h in the indicated
concentrations of K145 in the
presence of 0.5% FBS was
determined by MTS assay.
Values are displayed as %
vehicle control (DMSO), mean
± SEM (n= 3–4)
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rise to various opposing signaling outcomes [1, 4]. There-
fore, the cellular functions of the SKs are largely dictated by
their subcellular localization, which has previously been
shown to be regulated by various interacting proteins. The
Fig. 7 SK2 inhibition attenuates neoplastic growth of U-251 cells
in vitro and in vivo. Anchorage-independent growth of U-251 cells
was tested using colony formation assays in soft agar, in the presence
of K145 (a), MP-A08 (b) and ABC294640 (c) or vehicle control (veh;
0.04% DMSO). Average colony numbers were quantified and are
graphed as mean (±SD) from triplicate wells (***p < 0.001, ****p <
0.0001; Student's unpaired two-tailed t-test). d Mice bearing U-251
xenografts were administered 30 mg/kg body weight K145 (n= 8) or
vehicle control (n= 9) intraperitoneally (i.p.) daily from day 8 fol-
lowing engraftment, and tumor volume assessed. Mean tumor
volumes ± SEM are shown. Statistical analysis on all data points was
performed by two-way ANOVA. After 3 weeks of treatment with
K145 or vehicle control, tumors were excised and assessed for: e
CD31-positive vessels by immunohistochemical staining, with an
example of images for each group shown, and CD31-positive vessels
per field of view quantified (*p < 0.05 by Student’s unpaired two-tailed
t-test); f tumor cell apoptosis by fluorescent TUNEL and nuclear DAPI
labeling and quantified by masking on DAPI-labeled nuclei and
counting TUNEL-positive nuclei, with an example of images for each
group shown (*p < 0.05 by two-tailed Mann–Whitney test for non-
parametric distributions of data); and g tumor cell proliferation by
Ki67 staining quantified by positive pixel analysis to yield the ratio of
Ki67-positive vs. -negative nuclei for each sample (p= 0.066 by two-
tailed Mann–Whitney test for non-parametric distributions of data). All
scale bars= 100 μm
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calcium and integrin-binding protein CIB1 mediates the
translocation of SK1 to the plasma membrane to promote
survival and proliferative signaling [7]; however, it is
unknown whether this mechanism also regulates SK2
plasma membrane localization. Translocation of the SKs to
the plasma membrane has also been reported upon immu-
noglobulin E-mediated cross-linking of the FcεRI receptor
on mast cells, mediated by an interaction with the Src
family kinases Lyn and Fyn [23]. However, prior to this
study, very little was known about the regulation of SK2 to
regions of the cell where it is known to promote cell cycle
arrest and cell death, such as the nucleus, endoplasmic
reticulum and mitochondria [24–27]. Therefore, uncovering
mechanisms by which SK2 is localized within the cell,
particularly toward these organelles, is critical in under-
standing how the opposing roles of SK2 are regulated. As
such, the studies outlined here have begun to decipher these
mechanisms by identifying dynein as a critical regulator of
SK2 subcellular localization which may therefore control
many of the functions of this enzyme.
GBM is the most common and aggressive primary
malignant form of brain cancer in adults, where patients
have a median survival of less than 15 months after diag-
nosis and a 5-year survival rate of 3–5% [28]. The current
standard of care for GBM patients is surgical resection of
the tumor, followed by radiotherapy and administration of
the chemotherapeutic agent temozolomide [28]. However,
GBM remains incurable and there is clearly a need for more
effective treatments. SK inhibitors have been proposed as
promising therapeutic agents to use in combination with
chemotherapy and/or radiotherapy in GBM [29], as SK-
mediated conversion of pro-apoptotic ceramide, which is
produced as a result of these therapies, to pro-proliferative
S1P has been implicated in the resistance of GBM tumor
cells to treatment-induced death [30, 31]. S1P levels are
elevated in GBM tissue samples compared with normal
gray matter [31], and S1P has been shown to mediate GBM
cell proliferation and invasiveness through activation of S1P
G protein-coupled receptors [32–34]. The relative impor-
tance in GBM of the two SK isoforms that produce S1P is,
however, unclear. While SK1 is consistently upregulated in
GBM and its expression correlates with poor patient sur-
vival [31, 35, 36], highly selective SK1 inhibitors have had
surprisingly inconsistent effects on reducing GBM cell
proliferation and viability [31, 37]. The efficacy of SK2-
selective inhibitors has not been previously examined in
GBM, potentially because the role of SK2 in cancer is
generally less well understood and, unlike SK1, evidence of
SK2 upregulation in GBM is inconsistent [31, 36, 38].
Interestingly, however, RNAi-mediated SK2 knockdown
has been shown to reduce GBM cell proliferation and sur-
vival to a greater extent than SK1 knockdown [35]. Nota-
bly, SK2 is highly expressed in the brain [39]; in fact, SK2
expression in the brain is considerably higher than SK1
expression and, as such, SK2 is responsible for the majority
of S1P production in this organ [40]. Here, we have
demonstrated that SK2 plasma membrane localization and
extracellular S1P production in GBM cells is negatively
regulated by IC1, which is heavily downregulated in GBM.
These findings provide an explanation for why SK2 con-
tributes more to GBM cell proliferation and survival than
SK1 [35], despite SK2 expression not being upregulated in
GBM.
Strikingly, we have also demonstrated that targeting SK2
in GBM cells via re-expression of IC1, or by direct phar-
macological SK2 inhibition, resulted in reduced tumor
growth in vivo, possibly due, in part, to decreased tumor-
associated angiogenesis. Drugs that target angiogenesis
have emerged as promising anti-cancer therapeutics and,
specifically, the antiangiogenic monoclonal vascular endo-
thelial growth factor-blocking antibody, bevacizumab
(Avastin), has been approved for use in patients with
Fig. 8 Schematic showing the mechanism by which dynein regulates
the subcellular localization of SK2, and how the loss of IC1 in glio-
blastoma cells impacts on this. Dynein interacts with SK2 via IC1 to
transport SK2 in a retrograde direction along microtubules towards the
microtubule-organizing center (MTOC) located adjacent to the
nucleus, resulting in reduced plasma membrane localization of SK2.
Loss of IC1 expression commonly observed in GBM ablates the
interaction of dynein with SK2, blocking its role in subcellular loca-
lization of SK2, resulting in increased plasma membrane localization
of SK2 and release of S1P from the cell via S1P transporters
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recurrent GBM. Given the important role of extracellular
S1P in mediating tumor-associated angiogenesis [19], our
findings suggesting an increase in plasma membrane-
localized SK2 in GBM as a result of IC1 downregulation
suggests that targeting SK2 in GBM may have beneficial
antiangiogenic effects.
Another interesting concept to consider is whether the
prominent plasma membrane localization of SK2 observed
in GBM cells is seen universally in other cancer types
where IC1 is significantly downregulated. According to our
broad gene expression analysis, IC1 is significantly down-
regulated in many human cancers (Fig. 3a), notably in
various subtypes of breast cancer across a number of
datasets. SK2 has been previously shown to localize pre-
dominantly to the plasma membrane in MDA-MB-453
breast cancer cells, where it was found to be required for
migration of these cells towards epidermal growth factor
[26]. Furthermore, SK2 knockdown in MCF-7 breast cancer
cells resulted in significantly reduced tumor growth in an
in vivo xenograft model [41]. Therefore, it is tempting to
speculate that the important interplay between SK2 and IC1
observed in GBM may also occur in other cancers,
including breast cancer, where loss of IC1 is observed.
However, given that IC1 is only highly expressed in the
brain, heart and skeletal muscle [42], it will remain to be
determined whether the ubiquitous IC2 isoform would
compensate for the decrease in IC1 in other tissues.
Additional work is required to further understand and
characterize the interaction between SK2 and dynein.
Retrograde-directed movement of dynein results in its
accumulation at the MTOC, and dynein is also found
associated with organelles such as the golgi, lysosomes and
endosomes [12]. Dynein, and the cargo that it transports,
have been shown previously to exhibit peri-nuclear locali-
zation [43, 44] very similar to that demonstrated here by
dynein IC and SK2 (Fig. 1d). Whether SK2 is being
sequestered to specific peri-nuclear organelles, in either a
house-keeping shuttling process or in response to certain
stimuli, and how it is then transported away from these
regions, are all questions that will require further attention.
Indeed, in some situations this may represent a negative
regulatory mechanism to prevent prolonged signaling of
SK2 at the plasma membrane.
Overall, in this study we have identified a novel inter-
action between SK2 and the cytoplasmic dynein complex,
and we have uncovered a new potential mechanism of SK2
dysregulation in cancer, whereby modulation of IC1
expression in GBM can regulate SK2 subcellular localiza-
tion and ultimately affect tumorigenic potential. This work
highlights the importance of investigating SK2 subcellular
localization, and not simply whether it is upregulated, in
determining whether pharmacologically targeting SK2 is
likely to have therapeutic benefits in certain cancers. As
such, this study offers a rationale for the use of SK2-specific
inhibitors as potential anti-cancer therapeutics in GBM.
Materials and methods
Antibodies
The following primary antibodies were utilized: anti-FLAG
(Clone M2 #F3165, Sigma-Aldrich), anti-HA (#H3663,
Sigma-Aldrich), anti-DYNC1IC (clone 74.1, #MAB1618,
Millipore), anti-dynactin p150 (#SC-135890, Santa Cruz
Biotechnology), anti-α-tubulin (#ab7291, Abcam), rabbit
anti-DYNC1I1 (#13808-1-AP, Proteintech), anti-DYNC1I2
(#ab96288, Abcam), anti-DYNC1LIC1 (#ab157468,
Abcam), anti-SK2 (#SP4621, ECM Biosciences; and
#17096-1-AP, Proteintech), anti-GFP (#600-101-215,
Rockland Immunochemicals), anti-PECAM-1 (CD31; #SC-
1506, Santa Cruz Biotechnology) and anti-Ki67 (#VP-
K452, Vector Laboratories).
Cell culture
HEK293 cells were purchased from ATCC (Manassas, VA,
USA), and cultured as previously described [45]. GBM
cells were cultured in minimal essential media (MEM; Life
Technologies), containing 10% fetal bovine serum (FBS), 2
mM L-glutamine, 1 mM sodium pyruvate, 1% non-essential
amino acids, penicillin (1.2 mg/ml) and streptomycin (1.6
mg/ml). Patient-derived primary GBM cell lines were
established as previously reported [46], and cultured in
serum-free KnockOut Dulbecco's modified Eagle's medium/
F-12 basal medium supplemented with StemPro NSC SFM
supplement, 2 mM GlutaMAX-I, 20 ng/ml epidermal
growth factor, 20 ng/ml fibroblast growth factor-β (Life
Technologies) on flasks coated with 1% Matrigel Matrix
(Corning). All cells were grown at 37 °C with 5% CO2 in a
humidified incubator and periodically tested for myco-
plasma contamination.
Mammalian expression constructs
Mammalian expression construct encoding SK2 was gen-
erated previously [47]. Human SK2b (Genbank Accession
number NM_020126) was PCR amplified from placenta




GGGCA-3′. The resultant PCR product was cloned into
pcDNA3 (Invitrogen) following digestion with BamHI and
EcoRI. SK2b was PCR amplified with primers 5′-TAGAA
TTCATGAATGGACACCTTGAAGC-3′ and 5′-
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TAGAATTCAGGGCTCCCGCC-CCG-3′, digested with
EcoRI and cloned into pGBKT7 (Clontech).
Human DYNC1I1 (NM_001135556) and DYNC1I2
(NM_001271786) were amplified from placenta cDNA and
hemagglutinin (HA) epitope-tagged at the 3′ end by PCR







products were cloned into pcDNA3 following digestion
with BamHI and EcoRI.
pCXNEO-IRES EGFP [8] was digested with XhoI and
SacI, blunted and re-ligated to produce pCX1NEO. A mod-
ified polylinker was introduced following digestion with
EcoRI and ligation of annealed kinased oligonucleotides 5′-
AATTCGGTACCGAGCTCGCTAGCGCGGCCGCCTC-
GAGC-3′ and 5′-AATTGCTCGAGGCGGCCGCGC-
TAGCGAGCTCGGTACCG-3′ to produce pCX3NEO.
EGFP was PCR amplified with oligonucleotide primers 5′-
TAGAATTCATGGTGA-GCAAGGGCGAG-3′ and 5′-
TACTCGAGCGGCCGCTCACTTGTACAGCTCGTCC-
ATGC-3′. The link/EGFP product was digested with EcoRI
and NotI and cloned into pCX3NEO. DYNC1I1 was PCR
amplified with T7 and 5′-TAGAATTCGGGGGCAGA-
TAACTCAACAGTGC-3′ and cloned into pCX3NEO-link/
EGFP following digestion with BamHI and EcoRI to pro-
duce pCX3NEO-DYNC1I1-EGFP. Sequencing verified
integrity and orientation of all cDNAs.
Yeast two-hybrid screen
The yeast two-hybrid screen, using full-length human SK2b
as bait, was performed using the Matchmaker Gold Gal4
Two-Hybrid System (Clontech) and a universal human
normalized cDNA library (Clontech) according to the




Transient transfection of DNA, or co-transfection of DNA
and siRNA into cells, was performed using Lipofecta-
mine™ 2000 (Invitrogen), as per the manufacturer’s pro-
tocol. Cell lysate preparation, immunoblotting and
immunoprecipitation was performed as previously descri-
bed [9, 45]. For immunoprecipitation of endogenous SK2,
C57/Bl6 mouse brain lysates were made as previously
described [49], and immunoprecipitation was performed
using anti-SK2 antibodies (ECM Biosciences).
siRNA knockdown
RNAi-mediated DYNC1I1 and DYNC1I2 knockdown was
performed using methods previously described [45], using
ON-TARGETplus non-targeting siRNA pool or human
DYNC1I1 and DYNC1I2 ON-TARGETplus SMARTpool
siRNA (Dharmacon) targeting the following sequences for
DYNC1I1: GGAAGGCACUGUUGAGUUA,
GGAAAUUCGUGCUAACAGA, CAAGGGAAGUAGU-




Generation of stable cell lines
To generate stable cell lines expressing DYNC1I1 as a
GFP-fusion protein, U-251 cells were transfected with
pCX3NEO-DYNC1I1-EGFP, or empty vector. At 48 h after
transfection, cells were sorted for low-level GFP-positive
cells using a FACSAria II cell sorter (BD Biosciences).
Stable GFP-positive pooled cell populations were obtained
by sorting for GFP another two times.
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR)
RNA extracted from GBM cells was used to generate
cDNA using the QuantiTect reverse transcription kit
(QIAGEN) according to the manufacturer’s protocol. Gene
expression was assessed by qRT-PCR using the QuantiTect
SYBR Green PCR kit (QIAGEN) as previously described
[49], using human DYNC1I1 primers TAAAGTTGGC-
CAGGACTCAG and CCAGGGCTCTTTC-AATTACC, or
human DYNC1I2 primers CCAGTTATGGCTCAACC-
CAA and TCAGAGTGCAAGATTTGTTGC. Relative
gene expression was normalized to GAPDH gene expres-
sion and analyzed by the comparative quantitation method
as previously described [49].
Immunofluorescence
Immunofluorescence staining and confocal imaging was
performed as previously described [45]. Co-staining of F-
actin was performed by incubating cells with AlexaFluor
647 Phalloidin (Molecular Probes) for 30 min at room
temperature. TUNEL analysis on tumor tissue was per-
formed as previously described [21].
Immunohistochemistry
PECAM-1(CD31) expression in formalin-fixed paraffin-
embedded tumor tissues was assessed as previously
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described [9]. Color development was carried out using
3,3′-diaminobenzidine tetrahydrochloride (DAB) reagent
(Dako). For Ki67 imaging bright field scanning was per-
formed using a NanoZoomer slide scanner (Hamamatsu).
Images were processed using ImageJ (National Institutes of
Health) or Imagescope (Aperio) software in a blinded
manner as previously described [50, 51].
Duolink® protein interaction assay
Interactions between endogenous SK2 and dynein IC in
HEK293 cells were assessed with the Duolink® in situ
proximity ligation assay kit (Sigma-Aldrich), as previously
described [49].
S1P formation assay
The rate of extracellular S1P formation from intact cells was
determined as previously described [52]. Briefly, cells were
seeded into 6-well plates and were grown in MEM con-
taining 10% FBS overnight. Cells, at 80% confluence, were
then labeled with 0.5 µCi of [3H]-sphingosine (Perkin-
Elmer, Rowville, VIC, Australia), delivered in serum-free
media (7.5% final serum concentration on cells), for 30 min.
The conditioned media were then collected and extracellular
[3H]-S1P generated in the conditioned medium was
extracted via a modified Bligh–Dyer extraction [52], and
analyzed by scintillation counting. Analyses were per-
formed in quadruplicate with data normalized to cell
number.
Cell viability assays
Relative viable GBM cell numbers after SK2 inhibitor
treatment were determined by CellTiter MTS assay (Pro-
mega) as per the manufacturer’s protocol.
Colony formation
Colony formation assays in soft agar were performed as
previously described [9]. After 14–21 days, images were
taken of five random fields of view per well using an
Olympus MVX10 microscope. Average colony number and
size was quantified using ImageJ software.
In vivo tumor models
Experiments involving mice were approved by the SA
Pathology/CALHN Animal Ethics Committee. To examine
the effect of IC1 re-expression on tumor growth, 5 × 106 U-
251 cells were injected subcutaneously into the flank of 9-
week-old female NOD/SCID mice. Mice were examined
daily and caliper measurements of palpable tumors were
taken. To examine the effects of K145 on tumor growth, U-
251 flank xenografts were established in 8-week-old female
NOD/SCID mice as described above, and tumors measured
daily. At 8 days post cell injection, mice were randomized
into two groups and administered K145 or 40% poly-
ethylene glycol 400 vehicle control intraperitoneally daily.
At the endpoint of both models, mice were humanely killed,
tumors excised, fixed in 10% formalin and paraffin
embedded or used for lysate preparation.
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